CoDiBio
Financiado
Continuous Digitalized Processes for Producing Biopharmaceuticals
Biopharmaceuticals are essential for the medical treatment of diseases like immune deficiencies, cancer, and diabetes, and provide an indispensable component to the health care system worldwide, as showcased by mRNA vaccines in th...
Biopharmaceuticals are essential for the medical treatment of diseases like immune deficiencies, cancer, and diabetes, and provide an indispensable component to the health care system worldwide, as showcased by mRNA vaccines in the recent pandemic. Despite this success, manufacturing is still based on traditional, outdated batch production technologies, and on process development procedures based on historical experience and empiricism leading to many inefficiencies, like very long values of time-to-market. There is an urgent need to introduce modern integrated, continuous, and fully digitalized production processes, to also cope with the upcoming cell and gene therapies and the emerging personalized medicine. I develop here revolutionary process development and operation methodologies to enable this.
These are based on a Digital Twin, which includes the first continuous, integrated and fully digitalized plant for producing mRNA. The engine are innovative hybrid models for each unit of the plant, which are updated on real time through continuous learning techniques. These provide the predictive capabilities needed for monitoring and control, knowledge transfer, scenario analysis and experimental planning.
I will develop a new generation of hybrid models and innovative machine learning algorithms and provide the experimental evaluation and validation of my methodologies. Other high precision continuous processes, like flow-chemistry for sustainable catalytic processes or microfluidics for the controlled synthesis of nanomaterials, will benefit from these results.
I am a recognised pioneer in the scientific foundations of continuous operation in biopharma. This inspired me in developing this disruptive Digital-Twin-based methodology and cope with the associated high risk. With about 110 PhD students advised in my career and now active in Academia and Industry, I know how to inspire a new generation of scientists with the novel science emerging from this project.
ver más
Duración del proyecto: 62 meses
Fecha Inicio: 2023-07-24
Fecha Fin: 2028-09-30
Fecha Fin: 2028-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-07-24
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-ADG:
ERC ADVANCED GRANTS
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
ARISTOTELIO PANEPISTIMIO THESSALONIKIS
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5